Adverum Biotechnologies, Inc. Common Stock Profile
About
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum?s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Info & Links
CEO
Laurent Fischer
Headquarters
100 CARDINAL WAY Redwood City, CA 94063, UNITED STATES
Adverum Biotechnologies, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
84.87M
Enterprise Value
-7.98M
Enterprise Value/EBITDA(ttm)
0.08
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
0.57
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
25.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
-678.35%
Return on Equity(ttm)
-65.14%
Return on Invested Capital(ttm)
-71.83%
Return on Assets(ttm)
-40.52%
Income Statement
Revenue(ttm)
1000.00K
Revenue Per Share(ttm)
0.05
Gross Profit(ttm)
1000.00K
EBITDA(ttm)3
-100.64M
Net Income Available to Common(ttm)
-94.11M
Diluted EPS(ttm)
-5.99
Share Statistics
Beta (5Y Monthly)
0.94
52-Week Change
-80.82%
S&P 500 52-Week Change
18.02%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
20.80M
Dividend Yield
0.00%
Float4
19.93M
% Held by Insiders
4.20%
% Held by Institutions
48.17%
Balance Sheet
Total Cash(mrq)
153.24M
Total Cash Per Share(mrq)
7.37
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
5.82%
Quick Ratio(mrq)
5.82%
Book Value Per Share(mrq)
6.93
Cash Flow
Operating Cash Flow Per Share(ytd)
-3.08
Free Cash Flow(ytd)
-64.54M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.